By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.
Accelerated access to safe and effective psychedelic-assisted therapy.
Albert Labs is the first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs.
Investor Portal Access
Access the Albert Labs Investor Portal. Here you can find all the documents you may require for due diligence.
Investing Summary
Investor Presentation
Corporate Highlights
Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.
First psychedelics company leveraging established, accelerated pathways to psychedelic-assisted therapies for patients with urgent, unmet needs across european and other international healthcare structures.
Albert Labs is a collaboration between leading academic research institutions and medical centers to swiftly provide access for patients whilst collecting data and obtaining reimbursement.
Developing scalable solutions to generate effectiveness data and access existing patient pools within world leading research and clinical networks for established niche indications.
Starting with cancer related anxiety & depression in end of life patients and moving into broader mental health indications – patients cannot wait 5+ years and big pharma are not developing solutions.
… View more in the Investing Summary
Downloads
Media Summary
Latest corporate tear sheet
Latest Press Release
.pdf copy of our latest Press Release
Key Personnel
Meet the Albert Labs team
Key research
Summary of key research publications
RSS Feed
Subscribe via RSS here.
Let us tell you more.
We will email you to start the conversation.